When was Beeline Therapeutics founded?

Beeline Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Beeline Therapeutics located?

Beeline Therapeutics is headquartered in San Francisco, United States.

Who is the current CEO of Beeline Therapeutics?

Michael Wyman of Beeline Therapeutics. They have also founded 1 company.

Is Beeline Therapeutics a funded company?

Beeline Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 28, 2019.

When was the latest funding round of Beeline Therapeutics?

Beeline Therapeutics' latest funding was a $***** Seed round on Mar 28, 2019, with participation from 1 investor. Its primary sector is Cell Therapy. In United States, the Cell Therapy sector has seen $275M in funding in 2026 to date.

Where does Beeline Therapeutics rank among its competitors?

Beeline Therapeutics ranks 525th amongst 475 active competitors, of which 165 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Tenaya Therapeutics, which secured $8M in Feb, 2025.

Who are the top competitors of Beeline Therapeutics?

Beeline Therapeutics' top competitors include ADMA Biologics, Tenaya Therapeutics and BioNTech. Among them, Tenaya Therapeutics secured the most recent funding round in February, 2025.

Beeline Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Most viewed in 2019

Beeline Therapeutics is a deadpooled company based in San Francisco (United States), founded in 2018 by Michael Wyman and Dimitre Simeonov. It operates as a Developer of cell therapeutics for immunological diseases. Beeline Therapeutics has raised $250K in funding from IndieBio. The company has 475 active competitors, including 165 funded and 128 that have exited. Its top competitors include companies like ADMA Biologics, Tenaya Therapeutics and BioNTech.

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Deadpooled

Total Funding

$250K in 1 round

Latest Funding Round

Seed, Mar 28, 2019, $*****

Investors

IndieBio

Ranked

525^th among 565 competitors

Similar Companies

ADMA Biologics & 563 more

View Beeline Therapeutics' full profile

Beeline Therapeutics has raised a total funding of $250K over 1 round. Its latest funding round was a Seed round on Mar 28, 2019 for $*****. 1 investor participated in its latest round. Beeline Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Beeline Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 28, 2019	2430392	Seed	2666752	4174602	3946940	1199077

Access funding benchmarks and valuations. Sign up today!

View details of Beeline Therapeutics's funding rounds and investors

The founders of Beeline Therapeutics are Michael Wyman and Dimitre Simeonov. Michael Wyman is the CEO of Beeline Therapeutics.

Here are the details of Beeline Therapeutics' key team members:

Michael Wyman: Co-Founder & CEO of Beeline Therapeutics.
Dimitre Simeonov: Co-Founder of Beeline Therapeutics.

View details of Beeline Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Beeline Therapeutics include ADMA Biologics, Tenaya Therapeutics and BioNTech. Here is the list of Top 10 competitors of Beeline Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	71/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	Fidelity Investments, RA Capital Management ... & 7 others	70/100
3rd	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
4th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	69/100
5th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
6th	Apellis Pharmaceuticals 2008, Crestwood (United States), Acquired	Developer of therapeutics for the treatment of rare diseases	$213M	Sectoral, VenBio & 21 others	68/100
7th	PureTech Health 2001, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual	67/100
8th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Deerfield & 5 others	67/100
9th	Vera Therapeutics 2016, San Francisco (United States), Public	Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases	$197M	Abingworth, Fidelity Investments & 13 others	66/100
10th	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	Amgen, NVentures & 14 others	66/100
525th	Beeline Therapeutics 2018, San Francisco (United States), Deadpooled	Developer of cell therapeutics for immunological diseases	$250K	IndieBio	16/100